Drummond Paris, Non-Executive Chairman
Drummond brings over thirty years of pharmaceutical industry operations and management experience to Karus. After joining Sandoz (now Novartis) in 1981 he rose to become Global Head of the Transplantation and Immunology Unit (Basel, Switzerland) and was appointed CEO & Country President of Novartis Pharmaceuticals UK in 2001. At Novartis, his responsibilities included the delivery of on-budget performance within the pharmaceutical business units; providing effective governance and performance overview in consumer health, Ciba Vision, animal health and manufacturing business. He also represented Novartis to key stakeholders. In addition to his chairmanship of Karus, Drummond is President of Kowa Pharmaceuticals Europe.
Ann Hacker, Non-Executive Director
In addition to her role as a non-executive director of Karus Therapeutics, Ann is a non-executive director of Frimley Park NHS Foundation Trust Hospital and a non-executive director of Noble Health Fund VCT Plc. She is also a Trustee of the William Harvey Research Foundation. Ann has worked in the healthcare industry for over 30 years and has held senior management positions with Lilly and Glaxo Pharmaceuticals (now GSK) as well as having been CEO of three venture capital backed life science companies, Biocompatibles International Plc, Deltex Medical Limited and Metris Therapeutics Limited. In addition, she has held directorships in a number of private and public healthcare companies and health related government organisations.
Andrew Mackie, Non-Executive Director
Andrew holds a BSc in biochemistry from Queen's University (Canada), an LLB from the University of London and an MBA from the London Business School where he graduated with distinction. Andrew brings fifteen years of industry experience in pre-clinical research, clinical development and business development. Having worked for both multinational pharmaceutical (Novartis, Sanofi-Aventis) and service (MDS) companies, Andrew joined the biotechnology sector at Antisoma, the oncology specialist, prior to its IPO. Joining initially to establish the clinical department and transition new molecules into development, his most recent role was to manage the company's strategic alliance with F Hoffman-La Roche and in-license new molecules for the company's pipeline through partnerships and acquisitions. Andrew is currently Head of Life Sciences at IP Group plc.
William Bains, Non-Executive Director
William is a scientist and serial entrepreneur. He joined Karus's Board in August 2005. After degrees at Oxford and Warwick and research posts in the UK and US, William worked for PA Consulting Group for 8 years before joining Merlin Biosciences in 1996, where he was responsible for technical input into the companies created with Merlin Fund I. In 1999 he founded Amedis Pharmaceuticals and was its founding CEO/CSO until end of 2001. Amedis was successfully sold to Paradigm Therapeutics in 2004. William is CEO of Delta G, a Cambridge based start up, sits on the Boards of MultiProSys and the SULIS Fund, and teaches entrepreneurship at Cambridge University.
Sue Sundström, Non-Executive Director
Ms Sundström is a graduate of LBS and Wharton. Her career includes 20 years with AstraZeneca where she was responsible for multi million dollar deals in life sciences, the sale of non-strategic companies and the creation of new companies in line with developing strategic priorities. Ms Sundström now operates as an independent consultant, holds 3 non-executive directorships in early stage life science companies and is Director, Life Science Enterprise at the University of Southampton where she has been responsible for licensing technology emanating from the University's world leading research as well as for the creation of several spin-out companies.
Dr A Ganesan, Non-Executive Director
Dr Ganesan is a Reader in the School of Chemistry at Southampton University. He is an internationally recognized expert in the field of natural-product chemistry. He is a founding member of the Royal Society of Chemistry's High Throughput Chemistry and New Technologies Group and sits on the editorial advisory board of the Journal of Combinatorial Chemistry, and QSAR & Combinatorial Science. He has chaired a number of key scientific conferences, including the 2003 ACS Perspectives and the 2004 Gordon Conference. In 2004, Ganesan became the first chemist to synthesize the complex natural product, Spiruchostatin A.
Simon Kerry PhD MBA, Chief Executive Officer
Simon is a business professional with over a decade of experience in creating and developing innovative life-science companies. Before joining Karus in early-2006, Simon was Director of Business Development at Ablynx (Ghent, Belgium), where he was responsible for securing a number of key alliances with major pharmaceutical companies. Prior to Ablynx, Simon was Director of Business Development at Isogenica (Cambridge, UK) and Active Biotech (Lund, Sweden) and has held other key commercial appointments at Actinova and Actigen (both Cambridge, UK) and at CAMR (Salisbury, UK). Simon has a PhD in medicinal chemistry and an executive MBA from Loughborough University Business School.
Stephen Shuttleworth PhD FRSC, Chief Scientific Officer
Stephen is an R&D leader with over a decade of experience in the pharmaceutical industry. Stephen has established a strong track-record in R&D management with a number of high-calibre companies on both sides of the Atlantic, including Celltech-Chiroscience (Cambridge, UK), Shire Pharmaceuticals Inc. (Montreal, Canada), Amgen, Inc. (San Francisco, California) where he was Associate Director of Chemistry, and Piramed Ltd (Slough, UK) where he was Director of Chemistry and PI3K Programme Leader. Prior to joining Karus he was Head of New Projects Development at Cancer Research UK. Stephen obtained his BSc and PhD in Chemistry at the University of Liverpool. He has authored more than 70 publications and patents, and is a Fellow of the Royal Society of Chemistry.
Karus Therapeutics Ltd
John Fairclough Centre
University of Southampton
Highfield
Southampton
Hampshire SO17 1BJ
United Kingdom